



Maturation of amyloid β fibrils alters their molecular stability†

 Stefan Becker,^c Karin Giller,^c Daniel Sieme^c and Nasrollah Rezaei-Ghaleh^{id}*^{ab}

 Cite this: *Phys. Chem. Chem. Phys.*, 2023, 25, 15099

 Received 21st March 2023,
 Accepted 12th May 2023

DOI: 10.1039/d3cp01276j

rsc.li/pccp

Little is known about how maturation of Alzheimer's disease-related amyloid β (A β) fibrils alters their stability and potentially influences their spreading in the brain. Using high-pressure NMR, we show that progression from early to late A β 40 aggregates enhances the kinetic stability, while ageing during weeks to months enhances their thermodynamic stability.

A remarkable feature of neurodegenerative diseases such as Alzheimer's disease (AD) is their progressive clinical and neuropathological course.^{1,2} Two neuropathological hallmarks of AD are the extracellular deposition of amyloid β (A β) peptide as senile plaques and the intracellular deposition of hyperphosphorylated tau protein as neurofibrillary tangles.² The A β and tau aggregation pathology starts several years earlier than the onset of clinical symptoms and spreads in the brains of AD patients following particular spatiotemporal patterns, potentially through prion-like propagation of protein aggregates.^{2–5} Several studies have shown that the amyloid fibrils undergo various biochemical modifications and structural rearrangements during the long prodromal phase of AD.^{6–9} Little, however, is known about how the maturation of AD-related amyloid fibrils alters their stability and thereby potentially affects their spreading in the brain.

Previous 2D IR spectroscopy-based studies of A β fibrils suggest slow structural changes likely due to the presence of mobile trapped water molecules in fresh fibrils, which are re-located and eventually lost over the course of years.⁸ The structural maturation of A β fibrils can also occur *in vivo*, as it was shown in transgenic mouse models of AD using fluorescence

probes of the internal structure of fibrils.⁹ High-pressure NMR is a powerful technique to detect structural alterations in protein systems if they are associated with changes in the degree of compaction.¹⁰ Recently, this technique has been utilized to quantify the stability of wild-type and modified A β and other fibrils.^{11–14} Here, we exploit high-pressure NMR and investigate the effect of potential structural maturation spanning months on the thermodynamic and kinetic stability of A β 40 fibrils.

First, the A β 40 aggregation condition was set up. The 0.4 mg mL⁻¹, *i.e.* ca. 95 μ M, solution of uniformly ¹⁵N,¹³C-labeled recombinant A β 40 was incubated at 37 °C under mild agitation. The pH was set at 7.4 and the solution contained 25 mM HEPES as buffer and 50 mM NaCl to partially screen out the net negative charges of A β 40 molecules and accelerate aggregation. The aliquots were taken from the same A β 40 sample at 6 h, 24 h, 48 h, one week and two months after starting incubation. The EM images demonstrated the presence of typical amyloid fibrils in all the studied samples (Fig. 1a). No significant difference in the morphology or size of the fibrils was observed at these incubation time points (the average diameter of individual fibrils were respectively 12.4 \pm 1.6, 13.5 \pm 1.6, 13.2 \pm 1.9, 13.5 \pm 3.6 and 13.9 \pm 2.8 nm). In addition, the 1D ¹H NMR spectra showed almost complete loss of A β 40's NMR signals after incubation, confirming the conversion of nearly all A β 40 monomers to NMR-invisible large aggregates (Fig. 1b). Overall, the EM and NMR data confirmed the predominant presence of A β 40 fibrils in samples taken at all five time points.

Amyloid fibrils are often less compact than the core of globular folded proteins and frequently contain internal water-excluded void volumes.^{15–17} Monomer dissociation from amyloid fibrils can therefore create access to the void volume and lead to filling of this space by the surrounding water molecules and consequently reduce the system volume.^{10,17,18} In addition, whenever monomer dissociation from amyloid fibrils is accompanied by salt bridge disruption, the electrostriction effect of separated charges on surrounding water can further reduce the system volume.¹⁹ The application of high

^a Institute of Physical Biology, Heinrich Heine University Düsseldorf, Universitätsstraße 1, D-40225 Düsseldorf, Germany.

E-mail: Nasrollah.Rezaei.Ghaleh@hhu.de

^b Institute of Biological Information Processing, IBI-7: Structural Biochemistry, Forschungszentrum Jülich, D-52428 Jülich, Germany

^c Department of NMR-based Structural Biology, Max Planck Institute for Multidisciplinary Sciences, Am Fassberg 11, D-37077 Göttingen, Germany

† Electronic supplementary information (ESI) available: Supplementary methods. See DOI: <https://doi.org/10.1039/d3cp01276j>






Fig. 1 Aggregation of A β 40 peptide into NMR-invisible fibrils after 6 h, 24 h, 48 h, 1 week and 2 months of incubation in aggregation condition, as revealed by EM images (a) and 1D ^1H NMR spectra (b). In (b), the loss of amide and aromatic proton signals indicates nearly complete conversion of monomeric A β 40 peptide into large aggregates. The remaining sharp signal at ~ 8.45 ppm originates from an unknown small molecule existing in the studied A β samples.

pressure to amyloid fibrils is therefore expected to push the system towards the state with lower volume, *i.e.* promote monomer dissociation from fibrils.

To address how the stability of A β aggregates changes over the course of incubation in the aggregation condition, the fibrillated A β 40 aliquots taken at the above-mentioned time points were transferred to pressure-resistant ceramic NMR tubes for NMR measurements at 2000 bar (200 MPa). As stated above, the measurement at ambient pressure of 1 bar did not show any significant NMR signal from A β 40 monomers (Fig. 1b).

However, upon a pressure rise to 2000 bar, the real-time 2D $^{15}\text{N}, ^1\text{H}$ HSQC experiments revealed gradual increase in the intensity of the A β 40 signals (Fig. 2a). The average time-dependent monomer release profiles were indistinguishable for samples aggregated for 6 or 24 hours (hence averaged and termed as “early-aggregate”) and for 48 hours and one week (hence averaged and termed as “late-aggregate”). As shown in Fig. 2b, the monomer release from early-aggregates was much faster than that of late-aggregates, whereas the final level of monomer release was nearly identical between them (around 65% and 62% of the freshly prepared A β sample). The characteristic time of monomer release from early-aggregates obtained through global fitting of residue-specific curves was 5.46 ± 0.17 h, while the corresponding value for late-aggregates was 25.29 ± 0.47 h, around 4-5 times longer than that of early-aggregates (see ESI,† Supplementary methods, for details on fitting). The A β 40 sample aggregated for two months (hence termed “aged-aggregate”) showed slow monomer release with a




Fig. 2 Pressure-induced monomer release from A β 40 aggregates. (a) 2D $^{15}\text{N}, ^1\text{H}$ HSQC of early- (top row), late- (middle row) and aged-aggregates (bottom row) of A β 40, measured after ca. 1 h (left column), 12 h (middle column) and 43 h (right column) of incubation at high pressure (2000 bar). A time-dependent increase in peak intensities is observed, indicating pressure-induced monomer dissociation from large NMR-invisible A β 40 aggregates. (b) Kinetics of pressure-induced monomer release from early- (green), late- (purple) and aged-aggregates (red) of A β 40, shown as the average (\pm SD) relative intensity of HSQC peaks in dependence of incubation time at 2000 bar. The solid lines of the same colours represent the respective fitted curves. See text for the definition of early-, late- and aged-aggregates.



characteristic time of 23.60 ± 0.56 h, very similar to that of late-aggregates. Strikingly, however, the final level of released monomer was considerably lower (around 40% of the freshly prepared A β sample). Overall, the time-dependent monomer release data clearly show that progression from early to late A β 40 aggregates in the course of hours to days and from late to aged aggregates in the course of weeks to months differentially alters the stability of A β 40 fibrils.

The time-dependent monomer release data shown in Fig. 2b represent pressure-induced monomer dissociation from A β 40 fibrils and their back-association to A β 40 fibrils. After sufficiently long time, a new thermodynamic equilibrium between monomer and fibrillar states of A β 40 is established at higher pressure. If we assume a simple two-state model consisting of monomers and fibrils (Fig. 3a), where A β 40 monomer

dissociation and back-association are respectively governed by first-order rate constants k_{off} and $k_{\text{on,app}}$, then $K_{\text{eq}} = k_{\text{on,app}}/k_{\text{off}}$ will represent the thermodynamic stability of A β 40 fibrils. On the other hand, the kinetic stability of A β 40 fibrils will be reflected in k_{off} , which is inversely related to the lifetime of A β 40 fibrils. Through fitting the monomer release data to the two-state model, the K_{eq} values of 0.54, 0.61 and 1.5 were obtained respectively for early-aggregates, late-aggregates and aged-aggregates of A β 40 (see ESI,[†] Supplementary methods, for details on fitting). The corresponding k_{off} values were $33.1 \pm 1.0 \times 10^{-6}$, $6.8 \pm 0.1 \times 10^{-6}$ and $4.7 \pm 0.1 \times 10^{-6} \text{ s}^{-1}$, respectively (Fig. 3b). The analysed data indicate prominent enhancement of the kinetic, but not thermodynamic, stability of A β 40 fibrils during progression from early- to late-aggregates. Further progression from late- to aged-aggregates however involves more prominent enhancement in the thermodynamic stability when compared with the kinetic stability.

Our results show that maturation of A β 40 fibrils over the course of aggregation involves (at least) two phases: “early maturation” in the course of hours to days during which the kinetic stability of A β 40 fibrils is enhanced, and “late maturation” in the course of weeks to months during which the thermodynamic stability of A β 40 fibrils are affected. Thermodynamic stability of A β 40 fibrils against pressure-induced monomer release is determined by the change in partial molar volume $\Delta V_{\text{F} \rightarrow \text{m}}$ from the fibrillar (F) to monomeric (m) state, while their kinetic stability is determined by the change in partial molar volume $\Delta V_{\text{F} \rightarrow \text{F}^*}$ from the fibrillar state to an intermediate transition state (F*) existing on the disaggregation path. Accordingly, during early maturation of A β 40 fibrils, the positive $\Delta V_{\text{F} \rightarrow \text{F}^*}$ increases, indicating that the partial molar volume of the transition F* state is increased, *i.e.* it becomes less compact. Conversely, during late maturation, the negative $\Delta V_{\text{F} \rightarrow \text{m}}$ decreases, indicating that the partial molar volume of fibrils is decreased, *i.e.* they become more compact (Fig. 3c). It should however be emphasized that the picture of A β fibril maturation presented above is qualitative and the few number of data points used in this study does not allow rigorous determination of the exact number and timing of fibril maturation phases.

A β fibrils exhibit a significant degree of morphological and structural heterogeneity, sometimes even within the same A β sample.^{20–22} If different polymorphs of A β fibrils have different thermodynamic stability, then the reversible A β monomer dissociation from fibrils and its back-association will gradually shift the fibril population distribution towards fibrillar species with higher thermodynamic stability. In addition, slow structural rearrangements within single A β fibrils may underlie the time-dependent enhancement of their stability. Our data provide experimental support for maturation-dependent enhancement in thermodynamic stability of A β fibrils over the course of weeks to months, accompanied by higher compaction of A β fibrils. In addition to a gradual shift of fibril population distribution towards more stable compact species, the loss of water molecules trapped in the core of A β fibrils, as demonstrated by previous 2D IR studies,^{8,23} and its consequent structural




Fig. 3 Kinetic analysis of pressure-induced monomer release from A β 40 aggregates, according to a two-state model composed of a fibrillar (F) and monomeric (m) state as shown in (a). The obtained rate constants $k_{\text{on,app}}$ and k_{off} governing the interconversion between F and m states are shown in (b), separately for early-, late- and aged-aggregates of A β 40. The obtained rate constants suggest the scheme shown in (c) on how the partial molar volumes of F, m and the transition F* states are altered during maturation of A β 40 aggregates. The maturation from early- to late-aggregates does not change the volume of the F state but increases that of the F* state. Further maturation to aged-aggregates decreases the volume of F* and particularly F states. These volume changes underlie the enhancement of the kinetic and thermodynamic stability of A β 40 aggregates against high-pressure monomer dissociation, respectively during early and late maturation phases.



adjustments may underlie the maturation-dependent changes in compaction level of A β fibrils and their thermodynamic stability. Further support for maturation-dependent changes in the hydration of fibrils can be obtained by direct observation of bound water molecules through solid-state NMR and deuterium-based magnetic relaxation dispersion (MRD) methods.^{24,25} The maturation-dependent changes in the stability of A β fibrils resembles the glass-like aging processes reported for proteins, including globular and intrinsically disordered proteins and protein condensates,^{26–28} and could in principle reflect the slow release of A β fibrils from the local kinetic traps (topological or energetic) existing in their energy landscapes.²⁷

Neurodegeneration-related deposition of A β and other proteins as amyloid fibrils often starts years before the onset of the first clinical symptoms.^{1,2} During this long prodromal phase, biochemical modifications of amyloid deposits may alter their properties and potentially act as a switch in the pathological course of neurodegenerative diseases.^{6,7} In addition to biochemical maturation, amyloid fibrils may undergo structural maturation similar to what is demonstrated here in *in vitro* conditions.⁹ The resultant alteration in the kinetic and thermodynamic stability of amyloid fibrils has neuropathological importance, as it can influence the spreading of amyloid pathology in the brain. It should, however, be noted that the temporal dynamics of AD is a complex process and the structural (and biochemical) maturation of A β fibrils constitutes only one aspect of this multifaceted *in vivo* process. Furthermore, our data suggest the potential importance of considering the structural difference between fresh and mature A β fibrils in structure-based development of molecular imaging probes in AD and other neurodegenerative diseases.²⁹

To conclude, we investigated how the maturation of A β 40 fibrils affects their stability against pressure-induced dissociation. Through real-time high-pressure NMR experiments, it was shown that there are roughly two phases of A β fibril maturation, an early phase within the course of hours to days during which the kinetic stability of A β fibrils is enhanced, and a late phase within the course of weeks to months during which the thermodynamic stability of A β fibrils is enhanced. The higher stability of mature A β fibrils indicates their higher degree of compaction. Overall, our data demonstrate the structural and stability changes of A β fibrils during maturation and highlights the potential importance of A β fibril maturation in the pathological course of Alzheimer's disease.

Author contributions

Conceptualization, methodology, investigation, funding acquisition, project administration, supervision, writing – original draft: NRG; visualization, formal analysis: NRG, DS; resources, writing – review & editing: SB, KG, DS, NRG.

Conflicts of interest

There are no conflicts of any sort to declare.

Acknowledgements

N. R.-G. acknowledges the Deutsche Forschungsgemeinschaft (German Research Foundation, DFG) for research grants RE 3655/2-1 and 3655/2-3. We thank Dr Dietmar Riedel and Gudrun Heim for electron microscopy imaging.

Notes and references

- 1 A. A. Tahami Monfared, M. J. Byrnes, L. A. White and Q. Zhang, *Neurol. Ther.*, 2022, **11**, 553–569.
- 2 M. A. DeTure and D. W. Dickson, *Mol. Neurodegener.*, 2019, **14**, 32.
- 3 R. Morales, K. Callegari and C. Soto, *Virus Res.*, 2015, **207**, 106–112.
- 4 M. Jucker and L. C. Walker, *Nature*, 2013, **501**, 45–51.
- 5 D. R. Thal, U. Rub, M. Orantes and H. Braak, *Neurology*, 2002, **58**, 1791–1800.
- 6 A. Rijal Upadhaya, I. Kosterin, S. Kumar, C. A. von Arnim, H. Yamaguchi, M. Fandrich, J. Walter and D. R. Thal, *Brain*, 2014, **137**, 887–903.
- 7 X. H. Li, S. Ospitalieri, T. Robberechts, L. Hofmann, C. Schmid, A. R. Upadhaya, M. J. Koper, C. A. F. von Arnim, S. Kumar, M. Willem, K. Gnoth, M. Ramakers, J. Schymkowitz, F. Rousseau, J. Walter, A. Ronisz, K. Balakrishnan and D. R. Thal, *Brain*, 2022, **145**, 3558–3570.
- 8 J. Q. Ma, H. Komatsu, Y. S. Kim, L. Liu, R. M. Hochstrasser and P. H. Axelsen, *ACS Chem. Neurosci.*, 2013, **4**, 1236–1243.
- 9 S. Nystrom, K. M. Psonka-Antonczyk, P. G. Ellingsen, L. B. G. Johansson, N. Reitan, S. Handrick, S. Prokop, F. L. Heppner, B. M. Wegenast-Braun, M. Jucker, M. Lindgren, B. T. Stokke, P. Hammarstrom and K. P. R. Nilsson, *ACS Chem. Biol.*, 2013, **8**, 1128–1133.
- 10 J. A. Caro and A. J. Wand, *Methods*, 2018, **148**, 67–80.
- 11 N. Rezaei-Ghaleh, M. Amininasab, S. Kumar, J. Walter and M. Zweckstetter, *Nat. Commun.*, 2016, **7**, 11359.
- 12 G. A. de Oliveira, M. A. Marques, C. Cruzeiro-Silva, Y. Cordeiro, C. Schuabb, A. H. Moraes, R. Winter, H. Oschkinat, D. Foguel, M. S. Freitas and J. L. Silva, *Sci. Rep.*, 2016, **6**, 37990.
- 13 F. Piccirilli, N. Plotegher, M. G. Ortore, I. Tessari, M. Brucale, F. Spinozzi, M. Beltramini, P. Mariani, V. Militello, S. Lupi, A. Perucchi and L. Bubacco, *Biophys. J.*, 2017, **113**, 1685–1696.
- 14 N. Rezaei-Ghaleh, M. Amininasab, K. Giller and S. Becker, *J. Phys. Chem. Lett.*, 2023, **14**, 1427–1435.
- 15 F. Meersman and C. M. Dobson, *Biochim. Biophys. Acta*, 2006, **1764**, 452–460.
- 16 K. Akasaka, A. R. Latif, A. Nakamura, K. Matsuo, H. Tachibana and K. Gekko, *Biochemistry*, 2007, **46**, 10444–10450.
- 17 R. Mishra and R. Winter, *Angew. Chem., Int. Ed.*, 2008, **47**, 6518–6521.
- 18 N. V. Nucci, B. Fuglestad, E. A. Athanasoula and A. J. Wand, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 13846–13851.
- 19 I. Danielewicz-Ferchmin, E. Banachowicz and A. R. Ferchmin, *Biophys. Chem.*, 2003, **106**, 147–153.
- 20 W. Close, M. Neumann, A. Schmidt, M. Hora, K. Annamalai, M. Schmidt, B. Reif, V. Schmidt, N. Grigorieff and M. Fandrich, *Nat. Commun.*, 2018, **9**, 699.



- 21 J. Meinhardt, C. Sachse, P. Hortschansky, N. Grigorieff and M. Fandrich, *J. Mol. Biol.*, 2009, **386**, 869–877.
- 22 A. T. Petkova, R. D. Leapman, Z. Guo, W. M. Yau, M. P. Mattson and R. Tycko, *Science*, 2005, **307**, 262–265.
- 23 Y. S. Kim, L. Liu, P. H. Axelsen and R. M. Hochstrasser, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 17751–17756.
- 24 K. T. Movellan, R. Dervisoglu, S. Becker and L. B. Andreas, *Angew. Chem., Int. Ed.*, 2021, **60**, 24075–24079.
- 25 E. Persson and B. Halle, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 6266–6271.
- 26 L. Herenyi, K. Szigeti, J. Fidy, T. Temesvari, J. Schlichter and J. Friedrich, *Eur. Biophys. J.*, 2004, **33**, 68–75.
- 27 I. L. Morgan, R. Avinery, G. Rahamim, R. Beck and O. A. Saleh, *Phys. Rev. Lett.*, 2020, **125**, 058001.
- 28 L. Jawerth, E. Fischer-Friedrich, S. Saha, J. Wang, T. Franzmann, X. Zhang, J. Sachweh, M. Ruer, M. Ijavi, S. Saha, J. Mahamid, A. A. Hyman and F. Julicher, *Science*, 2020, **370**, 1317–1323.
- 29 M. Fandrich, S. Nystrom, K. P. R. Nilsson, A. Bockmann, H. LeVine, 3rd and P. Hammarstrom, *J. Intern. Med.*, 2018, **283**, 218–237.

